Chronic Stress-Induced m7G Cap Modification of ADRB2 Dysregulates the Pentose Phosphate Pathway to Promote Esophageal Squamous Cell Carcinoma Progression.
Aug 2026· Cancer Research· pp. OF1-OF19· 0 citations
Medicine
TL;DR
An RNMT-ADRB2-MYCBP-PPP axis that integrates epitranscriptomic regulation with adrenergic signaling to promote metabolic reprogramming and malignant progression in ESCC is defined.
Abstract
Chronic stress is increasingly recognized as a driver of cancer metabolism, highlighting the need to elucidate the mechanism linking chronic stress to metabolic reprogramming. Here, we performed untargeted metabolomics on serum samples from esophageal squamous cell carcinoma (ESCC) patients and integrated the results with clinical and stress-related assessments, revealing pentose phosphate pathway (PPP) enrichment accompanied by elevated epinephrine levels in patients with stress-associated features. β2-adrenergic receptor (ADRB2) activated by chronic stress stabilized MYCBP by competitively displacing VHL, thereby enhancing MYC transcriptional activity and upregulating key PPP enzymes, including G6PD and TKT. Unexpectedly, stress-associated stimulation not only activated ADRB2 signaling but also increased ADRB2 protein abundance. Mechanistically, stress exposure enhanced RNMT-dependent N7-methylguanosine (m7G) cap modification of ADRB2 mRNA, thereby increasing its translational efficiency. Together, these findings define an RNMT-ADRB2-MYCBP-PPP axis that integrates epitranscriptomic regulation with adrenergic signaling to promote metabolic reprogramming and malignant progression in ESCC. The stress-associated RNA modification-metabolism circuitry comprises potential therapeutic targets to overcome stress-associated ESCC progression.
Cervical cancer (CC) is a major threat to women's health globally, and the development of cisplatin (DDP) resistance is a key factor leading to treatment failure. Prior research from our group has demonstrated the significant involvement of stanniocalcin-2 (STC2) in mediating DDP-resistance in CC. This study explores t...
Shan-Shan Jin, Dong-Qi Gao, Ya-Ling Xiahou et al.· Acta Biochimica et Biophysic...· 0 citations
Cell metabolism is intricately interconnected with various pathological processes, including metabolic disorders, chronic inflammation, and tumor progression. Dysregulated lipid metabolism can result in mitochondrial dysfunction and excessive reactive oxygen species accumulation, which are well-established triggers f...
Mi-Sha Mao, Hao-Tian Liu, Jiang-Jiang Qin et al.· Cell Death & Disease· 0 citations
A novel METTL3/ELF1/GPX4 axis through which METTL3 promotes TNBC growth by regulating oxidative stress and ferroptosis-related markers is suggested, providing a basis for further investigation of this pathway in the context of TNBC biology and therapeutic development.
Jin-Chen Wang, Wei Wang, Jun-Jie Hu et al.· Asia-Pacific Journal of Clin...· 0 citations
Although aerobic glycolysis is a hallmark of hepatocellular carcinoma (HCC) progression, the underlying epitranscriptomic mechanisms remain poorly understood. Here, we identify METTL15, an N4-methylcytidine (m4C) RNA methyltransferase, as a novel oncogenic driver of this metabolic reprogramming. METTL15 is significantl...
Longhui Xie, Ken Ning, Yu-Hu Wang et al.· International Journal of Bio...· 0 citations
Mechanistic investigations demonstrated that NAT10 elevates MARK2 expression, activating the mTOR/HIF-1α/C-Myc signaling cascade, thereby promoting aerobic glycolysis in PCa cells, suggesting that targeting ac4C mRNA modifications may provide a novel therapeutic strategy for managing prostate cancer.
Yi-Ming Zhang, Jian Wang, Gan-Ping Wang et al.· Cancer Gene Therapy· 0 citations
Triple-negative breast cancer (TNBC) lacks actionable therapeutic targets and remains highly dependent on cytotoxic chemotherapy, yet the rapid emergence of cisplatin resistance severely limits clinical benefits. The molecular mechanisms underlying this resistance and effective combination strategies remain incompletel...
Ming-Kai Gong, Fan Liang, Hu Wang et al.· Drug resistance updates· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.